Toronto, June 24th, 2022 – Vivariant Laboratories Inc. – (the “Company” or “Vivariant”) is pleased to announce it has received its Drug Establishment License (DEL) number from Health Canada.

In another step forward, Vivariant has received Good Manufacturing Practices (GMP) certification by way of a Drug Establishment License (DEL) from Health Canada. This accreditation permits the company to test pharmaceutical drugs and other products with a Drug Identification Number (DIN). Vivariant applied for the DEL in February 2022 which was followed by a site audit by Health Canada in May.

Good Manufacturing Practices are the core of quality assurance that ensures products are safe and consistently produced. As such, there is also a growing demand for GMP certified laboratories in the Canadian Cannabis industry, particularly from extractors and manufacturers of products of high quality.

“Not only will this allow us to expand into pharmaceutical testing, it will also bolster our reputation for our existing business in the cannabis, dietary supplement/natural health product and cosmetic industries we have been servicing to date.” President & Founder, Thomas Fraleigh remarked. “It has been an honour to work with such an amazing team and I am excited for the future.”

Established in 2017, Vivariant is headquartered in Mississauga, Ontario and specializes in analytical chemistry and microbiology testing services for the Cannabis, Cosmetics, and Dietary Supplement/Natural Health Product industries. Vivariant already holds ISO 17025:2017 accreditation and an Analytical Testing license under the Cannabis Act.